Affordable Access

deepdyve-link
Publisher Website

Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value: A Multicentric 11C-Methionine and 18F-FDOPA PET Experience.

Authors
  • Zaragori, Timothée1, 2
  • Castello, Angelo3
  • Guedj, Eric4, 5
  • Girard, Antoine6
  • Galldiks, Norbert7, 8, 9
  • Albert, Nathalie L10
  • Lopci, Egesta3
  • Verger, Antoine1, 2
  • 1 From the Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine.
  • 2 Université de Lorraine, IADI, INSERM U1254, Nancy, France. , (France)
  • 3 Nuclear Medicine Department, Humanitas Clinical and Research Hospital-IRCCS, Rozzano, Italy. , (Italy)
  • 4 Nuclear Medicine Department, APHM, Timone Hospital.
  • 5 Aix Marseille Univ, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, CERIMED, Marseille.
  • 6 Department of Nuclear Medicine, Eugène Marquis Center, Rennes 1 University, Rennes, France. , (France)
  • 7 Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne.
  • 8 Inst. of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich.
  • 9 Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf.
  • 10 Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. , (Germany)
Type
Published Article
Journal
Clinical nuclear medicine
Publication Date
Jan 01, 2021
Volume
46
Issue
1
Identifiers
DOI: 10.1097/RLU.0000000000003240
PMID: 32804767
Source
Medline
Language
English
License
Unknown

Abstract

The aim is to explore the concept of photopenic defects in newly diagnosed glioma patients with the 2 widely used C-MET and F-FDOPA PET amino acid tracers. Thirty-two C-MET and 26 F-FDOPA PET scans with amino acid PET-negative gliomas were selected in this European multicentric study. Of these gliomas, 16 C-MET and 10 F-FDOPA PET scans with photopenic defects were identified, exhibiting lower mean tumor-to-background ratio as compared with isometabolic gliomas (P < 0.001). Gliomas with photopenic defects had no different progression-free survival than isometabolic gliomas in the whole population (P = 0.40), but shorter progression-free survival in the subgroup of World Health Organization grade II IDH-mutant astrocytomas (35 vs 68 months; P = 0.047).

Report this publication

Statistics

Seen <100 times